In their respective phase 3 trials, Wegovy pill produced a slightly larger average weight loss (around 13.6% over 64 weeks) than Foundayo (between 11.2% & 12.4% over 72 weeks at the highest tested dose)
Patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) with concurrent diabetes or obesity might benefit from the hepatic anti-inflammatory effects observed in clinical studies, though GLP-1 receptor agonists are not yet FDA-approved specifically for liver disease
Choose low-sugar options or dilute sports drinks to avoid excessive carbohydrate intake
S.BrndstedL.KankamM.MorelliG.NguyenD.SkjthT
The NovoCare Patient Assistance Program (PAP) can help with Ozempic costs by providing free Ozempic to eligible individuals
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, et al